Free tool
FAERS Monitor: Akovaz
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208289 or its brand name (Akovaz, Ephedrine Sulfate). Reports on generic versions are filed under their own applications.
Reports
162
Serious
117
72% of reports
Hospitalization
46
Death reported
22
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective25
- drug abuse14
- cardiac arrest13
- toxicity to various agents13
- overdose12
- respiratory arrest11
- administration related reaction10
- hypotension10
- no adverse event10
- off label use10
- drug hypersensitivity9
- nausea8
- pain8
- acute kidney injury7
- anxiety7
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 4 |
| 2008 | 4 |
| 2009 | 2 |
| 2010 | 6 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 4 |
| 2015 | 1 |
| 2016 | 5 |
| 2017 | 8 |
| 2018 | 20 |
| 2019 | 13 |
| 2020 | 10 |
| 2021 | 15 |
| 2022 | 8 |
| 2023 | 17 |
| 2024 | 18 |
| 2025 | 13 |
| 2026 | 10 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,997 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| administration related reactionSignal | 10 | 7025.0 | 3788.8 | 60,132 |
| respiratory arrestSignal | 11 | 51.9 | 29.3 | 499 |
| drug abuseSignal | 14 | 21.8 | 13.2 | 259 |
| cardiac arrestSignal | 13 | 20.4 | 12.1 | 222 |
| toxicity to various agentsSignal | 13 | 10.0 | 5.9 | 97 |
| overdoseSignal | 12 | 7.2 | 4.2 | 59 |
| no adverse eventSignal | 10 | 7.2 | 3.9 | 47 |
| hypotensionSignal | 10 | 6.5 | 3.6 | 41 |
| drug hypersensitivitySignal | 9 | 6.0 | 3.2 | 33 |
| acute kidney injurySignal | 7 | 5.9 | 2.9 | 24 |
| anxietySignal | 7 | 3.2 | 1.5 | 9 |
| drug ineffectiveSignal | 25 | 2.5 | 1.7 | 22 |
| pain | 8 | 1.7 | 0.9 | 2 |
| off label use | 10 | 1.5 | 0.8 | 1 |
| nausea | 8 | 1.3 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.